Table 2.
Variable |
AutoHCT (n = 7888) |
Adult alloHCT (n = 16 558) |
Pediatric alloHCT (n = 1820) |
|||
---|---|---|---|---|---|---|
Unadjusted HR (95% CI); P value | Adjusted HR∗ (95% CI); P value | Unadjusted HR (95% CI); P value | Adjusted HR† (95% CI); P value | Unadjusted HR (95% CI); P value | Adjusted HR‡ (95% CI); P value | |
Race | ||||||
NHWs | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
NHAAs | 0.85 (0.76-0.95); .004 | 0.91 (0.81-1.03); .12 | 1.12 (1.03-1.21); .005 | 1.13 (1.04-1.22); .004 | 1.76 (1.4-2.2); <.001 | 1.62 (1.3-2.03); <.001 |
Hispanics | 0.93 (0.77-1.11); .41 | 1.04 (0.87-1.25); .66 | 0.91 (0.84-0.99); .03 | 1.01 (0.92-1.1); .89 | 1.22 (1.02-1.46); .03 | 1.17 (0.97-1.41); .10 |
Others | 0.81 (0.64-1.030); .09 | 0.83 (0.65-1.05); .13 | 0.91 (0.82-1.01); .08 | 0.97 (0.87-1.07); .50 | 1.52 (1.15-2.02); .004 | 1.47 (1.11-1.96); .008 |
Year of transplant | ||||||
2009-2010 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
2011-2012 | 0.78 (0.68-0.9); .0006 | 0.89 (0.77-1.03); .13 | 1.01 (0.94-1.08); .84 | 0.91 (0.85-0.98); .014 | 1.00 (0.79-1.26); .99 | 1.05 (0.83-1.32); .71 |
2013-2014 | 0.77 (0.67-0.87); <.001 | 0.78 (0.69-0.9); .0004 | 0.93 (0.87-0.99); .015 | 0.81 (0.76-0.86); <.001 | 0.77 (0.63-0.94); .01 | 0.75 (0.6-0.93); .008 |
2015-2016 | 0.75 (0.65-0.86); <.001 | 0.72 (0.62-0.83); <.001 | 0.91 (0.85-0.97); .003 | 0.78 (0.73-0.83); <.001 | 0.56 (0.44-0.7); <.001 | 0.53 (0.42-0.68); <.001 |
2017-2018 | 0.60 (0.5-0.72); <.001 | 0.60 (0.5-0.72); <.001 | 0.75 (0.7-0.81); <.001 | 0.66 (0.61-0.71); <.001 | 0.74 (0.57-0.96); .03 | 0.71 (0.54-0.92); .01 |
CI, confidence interval; HR, hazard ratio.
Other significant variables include patient age, sex, diagnosis, disease status, HCT-CI, KPS, and marital status.
Other significant variables include patient age, diagnosis, disease risk, HCT-CI, KPS, insurance, and donor type.
Other significant variables include disease status at HCT, HCT-CI, and recipient cytomegalovirus status.